ARKG vs IBB

Key Takeaways

• ARKG is an actively managed thematic ETF targeting the genomics revolution with concentrated holdings in innovative healthcare companies, while IBB is a passive ETF providing broad exposure to the biotechnology sector.
• ARK Genomic Revolution ETF (ARKG) typically holds 30-40 stocks with heavy concentration in a few genomics-focused names, whereas iShares Biotechnology ETF (IBB) holds over 240 securities for greater diversification.
• Expense ratios differ notably: ARKG charges 0.75%, compared to IBB's 0.44%, reflecting ARKG's active management versus IBB's index-tracking approach.
• Both ETFs allocate nearly 100% to healthcare, but ARKG emphasizes disruptive genomics technologies such as gene editing and bioinformatics, while IBB covers a wider range of established and emerging biotechnology firms.
• ARKG exhibits higher volatility due to its concentrated thematic bets, whereas IBB offers more stable exposure through its modified market-capitalization weighting and broader holdings base.
• Structural differences position ARKG for investors seeking high-conviction innovation exposure and IBB for those preferring cost-efficient, diversified sector access.

Introduction

ARK Genomic Revolution ETF (ARKG) and iShares Biotechnology ETF (IBB) both target healthcare innovation but pursue distinct strategies within the biotechnology space. ARKG focuses on the genomics revolution through active stock selection, while IBB delivers broad, passive exposure to the biotechnology industry via an index-tracking methodology. These ETFs appeal to investors seeking growth in life sciences but differ in risk, cost, and thematic depth. The comparison highlights how active thematic approaches contrast with established sector benchmarks amid ongoing advancements in gene therapies, diagnostics, and drug development.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014 that seeks long-term capital growth by investing at least 80% of assets in domestic and foreign equity securities of companies involved in the genomics revolution. The fund typically holds 30-40 stocks, with top positions including 10x Genomics Inc (TXG), Twist Bioscience Corp (TWST), Tempus AI Inc (TEM), CRISPR Therapeutics AG (CRSP), and Absci Corp (ABSI). Holdings concentrate in healthcare, particularly genomics, gene editing, and bioinformatics. The expense ratio stands at 0.75%. As a non-diversified, actively managed vehicle, ARKG features dynamic rebalancing driven by ARK Investment Management's thematic research rather than mechanical index rules.

iShares Biotechnology ETF (IBB) Overview

iShares Biotechnology ETF (IBB) is a passively managed fund launched in 2001 that seeks to track the performance of the NYSE Biotechnology Index, composed of U.S.-listed equities primarily engaged in biotechnology. The ETF holds approximately 240 securities with top holdings such as Gilead Sciences Inc (GILD), Amgen Inc (AMGN), Vertex Pharmaceuticals Inc (VRTX), Regeneron Pharmaceuticals Inc (REGN), and Moderna Inc (MRNA). Sector allocation is almost entirely healthcare, spanning biotechnology, life sciences tools, and pharmaceuticals. The expense ratio is 0.44%. IBB employs modified market-capitalization weighting with quarterly rebalancing to maintain alignment with its benchmark, offering broad diversification across market capitalizations.

Industry and Thematic Backdrop

The biotechnology sector continues to benefit from advances in gene editing, personalized medicine, and AI-driven drug discovery. Regulatory pathways for novel therapies remain active, while macroeconomic factors such as interest rate expectations influence capital flows into growth-oriented healthcare names. Broader risks include clinical trial outcomes, patent expirations, and potential policy changes affecting drug pricing. Both ETFs operate within this environment, with ARKG positioned toward early-stage genomic innovations and IBB capturing established biotechnology leaders alongside emerging players.

Performance and Positioning Comparison

In recent market cycles, ARKG has shown greater sensitivity to sentiment around genomics breakthroughs due to its concentrated active bets, resulting in higher volatility compared to the more stable trajectory of IBB. IBB's diversified holdings across large-cap biotechnology firms have provided relative resilience during sector rotations driven by earnings cycles and macroeconomic shifts. ARKG's thematic focus may amplify gains during periods of innovation momentum, while IBB's passive structure supports consistent exposure with lower turnover. Relative positioning favors IBB for investors prioritizing cost efficiency and breadth, whereas ARKG suits those aligned with specific disruptive themes.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights into ETFs like ARKG and IBB can leverage this platform for informed decision-making.

Tickeron AI Verdict

Based on structural factors including lower expense ratio, broader diversification, and established index methodology, Tickeron’s AI would currently assign a higher probability of favor to iShares Biotechnology ETF (IBB). Its cost efficiency and reduced concentration risk provide a more balanced profile for sustained sector exposure, though ARKG may appeal in environments favoring concentrated thematic momentum.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations